Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 114; no. 52; pp. E11257 - E11266
• Main Authors: Lessard, Samuel, Francioli, Laurent, Alfoldi, Jessica, Tardif, Jean-Claude, Ellinor, Patrick T., MacArthur, Daniel G., Lettre, Guillaume, Orkin, Stuart H., Canver, Matthew C.
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 26.12.2017
• Series: PNAS Plus
• Subjects: Biological Sciences; Biological variation; Cell lines; CRISPR; CRISPR-Cas Systems; Design optimization; Editing; Gene sequencing; Genetic diversity; Genetic Loci; Genetic Therapy; Genomes; gRNA; Humans; Loci; Nuclease; PNAS Plus; Polymorphism; Polymorphism, Single Nucleotide; Ribonucleic acid; RNA; RNA, Guide, CRISPR-Cas Systems - genetics; Safety; Single-nucleotide polymorphism; Toxicity; off-target specificity; CRISPR-Cas9; human genetic variation; therapeutic genome editing; on-target specificity
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.1714640114

The CRISPR-Cas9 nuclease system holds enormous potential for therapeutic genome editing of a wide spectrum of diseases. Large efforts have been made to further understanding of on- and off-target activity to assist the design of CRISPR-based therapies with optimized efficacy and safety. However, current efforts have largely focused on the reference genome or the genome of cell lines to evaluate guide RNA (gRNA) efficiency, safety, and toxicity. Here, we examine the effect of human genetic variation on both on- and off-target specificity. Specifically, we utilize 7,444 whole-genome sequences to examine the effect of variants on the targeting specificity of ∼3,000 gRNAs across 30 therapeutically implicated loci. We demonstrate that human genetic variation can alter the off-target landscape genome-wide including creating and destroying protospacer adjacent motifs (PAMs). Furthermore, single-nucleotide polymorphisms (SNPs) and insertions/deletions (indels) can result in altered on-target sites and novel potent off-target sites,which can predispose patients to treatment failure and adverse effects, respectively; however, these events are rare. Taken together, these data highlight the importance of considering individual genomes for therapeutic genome-editing applications for the design and evaluation of CRISPR-based therapies to minimize risk of treatment failure and/or adverse outcomes.